Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study (Q42472764)

1 November 2017

title

Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study (English)

1 reference

1 November 2017

Basil I Hirschowitz

1

1 reference

1 November 2017

Julie Simmons

series ordinal

2

1 reference

1 November 2017

Jean Mohnen

series ordinal

3

1 reference

1 November 2017

language of work or name

English

0 references

publication date

1 January 2005

1 reference

Clinical Gastroenterology and Hepatology

1 November 2017

published in

1 reference

1 November 2017

volume

3

1 reference

1 November 2017

issue

1

1 reference

1 November 2017

page(s)

39-48

1 reference

Long-term lansoprazole control of gastric acid and pepsin secretion in ZE and non-ZE hypersecretors: a prospective 10-year study

1 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900606-8

7 January 2021

Long-term treatment with lansoprazole of patients with duodenal ulcer and basal acid output of more than 15 mmol/h

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900606-8

7 January 2021

Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900606-8

7 January 2021

Surgery in Zollinger-Ellison syndrome alters the natural history of gastrinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900606-8

7 January 2021

Benign and malignant gastrinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900606-8

7 January 2021

Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900606-8

7 January 2021

Surgery to cure the Zollinger-Ellison syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900606-8

7 January 2021

Assessment and prediction of long-term cure in patients with the Zollinger-Ellison syndrome: the best approach.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900606-8

7 January 2021

Effects of curative gastrinoma resection on gastric secretory function and antisecretory drug requirement in the Zollinger-Ellison syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900606-8

7 January 2021

Prospective study of the need for long-term antisecretory therapy in patients with Zollinger-Ellison syndrome following successful curative gastrinoma resection.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900606-8

7 January 2021

Studies on the interrelation between Zollinger-Ellison syndrome, Helicobacter pylori, and proton pump inhibitor therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900606-8

7 January 2021

Long-term treatment with lansoprazole for patients with Zollinger-Ellison syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900606-8

7 January 2021

Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900606-8

7 January 2021

Vagal effects on acid and pepsin secretion and serum gastrin in duodenal ulcer and controls

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900606-8

7 January 2021

Reflux esophagitis in patients with Zollinger-Ellison syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900606-8

7 January 2021

Use of omeprazole in Zollinger-Ellison syndrome: a prospective nine-year study of efficacy and safety.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900606-8

7 January 2021

Currently used doses of omeprazole in Zollinger-Ellison syndrome are too high

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900606-8

7 January 2021

Long-term efficacy and safety of omeprazole in patients with Zollinger-Ellison syndrome: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900606-8

7 January 2021

Use of omeprazole in patients with Zollinger-Ellison syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900606-8

7 January 2021

Prospective study of efficacy and safety of lansoprazole in Zollinger-Ellison syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900606-8

7 January 2021

Minor effects of Helicobacter pylori on gastric secretion and dose of lansoprazole during long-term treatment in ZE and non-ZE acid hypersecretors

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900606-8

7 January 2021

Risk factors for esophagitis in extreme acid hypersecretors with and without Zollinger-Ellison syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900606-8

7 January 2021

Healing and relapse of reflux esophagitis during treatment with ranitidine.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900606-8

7 January 2021

Is there any acid peptic disease that is refractory to proton pump inhibitors?

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900606-8

7 January 2021

Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900606-8

7 January 2021

Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900606-8

7 January 2021

Omeprazole, hypergastrinemia, and gastric carcinoid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900606-8

7 January 2021

Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900606-8

7 January 2021

Gastric secretion in Zollinger-Ellison syndrome. Correlation with clinical expression, tumor extent and role in diagnosis--a prospective NIH study of 235 patients and a review of 984 cases in the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900606-8

7 January 2021

Medical management of patients with Zollinger-Ellison syndrome who have had previous gastric surgery: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900606-8

7 January 2021

Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900606-8

7 January 2021

Healing and relapse of severe peptic esophagitis after treatment with omeprazole

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900606-8

7 January 2021

10.1016/S1542-3565(04)00606-8

Identifiers

DOI

1 reference

1 November 2017

1 reference